Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 13 (1), 1-16

Engineering of Exosomes to Target Cancer Metastasis


Engineering of Exosomes to Target Cancer Metastasis

Zhenjiang Zhang et al. Cell Mol Bioeng.


As a nanoscale subset of extracellular vehicles, exosomes represent a new pathway of intercellular communication by delivering cargos such as proteins and nucleic acids to recipient cells. Importantly, it has been well documented that exosome-mediated delivery of such cargo is involved in many pathological processes such as tumor progression, cancer metastasis, and development of drug resistance. Innately biocompatible and possessing ideal structural properties, exosomes offer distinct advantages for drug delivery over artificial nanoscale drug carriers. In this review, we summarize recent progress in methods for engineering exosomes including isolation techniques and exogenous cargo encapsulation, with a focus on applications of engineered exosomes to target cancer metastasis.


Figure 1
Figure 1
Exosome biogenesis. Formation of exosomes begins with membrane invagination in the form of an endosome, leading to the development of the early endosome. Upon maturation, the endosome becomes a multivesicular endosome, which releases its contents in the form of exosomes.
Figure 2
Figure 2
Illustration of exosome engineering through parental cells (upper) and post isolation (lower). Parental cells can be genetically modified to express desirable therapeutic protein or nucleic acids. Drugs can be encapsulated inside parental cells simply by coincubation or electroporation. The exosome surface can be modified with imaging or therapeutic molecules by chemistry or other conjugation methods. Hydrophilic drugs can be encapsulated inside exosomes via simple co-incubation or electroporation while hydrophobic drugs are inserted into the hydrophobic core of the lipid bilayer membrane of exosomes.

Similar articles

See all similar articles


    1. Alvarez-Erviti L, et al. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat. Biotechnol. 2011;29(4):341–345. doi: 10.1038/nbt.1807. - DOI - PubMed
    1. André F, et al. Tumor-derived exosomes: a new source of tumor rejection antigens. Vaccine. 2002;20:A28–A31. doi: 10.1016/S0264-410X(02)00384-5. - DOI - PubMed
    1. André F, et al. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells. J. Immunol. 2004;172(4):2126–2136. doi: 10.4049/jimmunol.172.4.2126. - DOI - PubMed
    1. Andreola G, et al. Induction of lymphocyte apoptosis by tumor cell secretion of FasL-bearing microvesicles. J. Exp. Med. 2002;195(10):1303–1316. doi: 10.1084/jem.20011624. - DOI - PMC - PubMed
    1. Antimisiaris SG, Mourtas S, Marazioti A. Exosomes and exosome-inspired vesicles for targeted drug delivery. Pharmaceutics. 2018;10(4):218. doi: 10.3390/pharmaceutics10040218. - DOI - PMC - PubMed

LinkOut - more resources